A biotechnology firm based in Boston has taken a significant step in the field of ageing research, administering a gene therapy to a human patient for the first time with the goal of reversing cellular deterioration. Life Biosciences announced that its experimental treatment, designated ER-100 (AAV2-OSK), has entered Phase 1 clinical trials, marking what the company calls the first-ever epigenetic restoration candidate approved for human testing.
The therapy relies on three proteins—Oct4, Sox2, and Klf4, collectively known as OSK factors—to perform partial epigenetic reprogramming. These proteins act as a reset mechanism, restoring cells to a younger state by reversing harmful epigenetic changes that accumulate over time due to ageing, lifestyle factors such as smoking or alcohol consumption, or disease. Unlike the DNA sequence, which remains largely stable throughout life, the epigenetic code—the system that controls which genes are active—can be altered by environmental and biological stressors, leading to conditions like cancer or neurological disorders.
“This is an important moment for Life Bio and for the field of ageing biology,” said David Sinclair, co-founder of Life Biosciences and a professor of genetics at Harvard Medical School. “Our research has suggested that ageing is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.”
Targeting Optic Nerve Damage
The initial clinical trial will enroll patients suffering from two serious eye diseases: open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION). Open-angle glaucoma is a chronic, progressive condition where the eye’s drainage system becomes clogged, leading to fluid buildup and increased intraocular pressure, which gradually damages the optic nerve and causes vision loss, often starting with peripheral vision. NAION, sometimes described as a mini-stroke of the optic nerve, results from reduced blood flow to the back of the eye, causing sudden vision loss, typically in one eye and often noticed upon waking.
If successful, ER-100 would represent the first instance of cellular rejuvenation in humans, according to the company. The approach builds on the Nobel Prize-winning work of Sir John B. Gurdon and Shinya Yamanaka, who demonstrated that ordinary cells could be reprogrammed into stem cells using similar factors. Life Biosciences has already tested the therapy in rodents and primates before moving to human trials.
Beyond eye diseases, the company is developing applications for other organs, including a second therapy for liver disease. The broader ambition is to deliver cell-resetting treatments across the body, addressing a range of age-related conditions. This field is attracting growing investment; Retro Biosciences, an American company backed by OpenAI’s Sam Altman, is also working on therapies to extend healthy lifespan by a decade.
While no therapeutic uses of Yamanaka factors have yet been approved, the momentum behind epigenetic reprogramming is building. For European readers, the implications are clear: ageing populations across the continent, from Berlin to Barcelona, face rising rates of chronic diseases such as glaucoma and neurodegeneration. If these therapies prove safe and effective, they could reshape healthcare strategies in EU member states and beyond. However, regulatory hurdles remain, and the European Medicines Agency will likely scrutinize any future applications for approval in Europe.
As the trial progresses, researchers and investors will watch closely. The first human dose is a milestone, but the path to a marketable therapy is long. For now, the focus is on safety and efficacy in a small group of patients with vision-threatening conditions.
